1226992-79-5

Upstream product

• 41838-46-4 4-Amino-1-methylpiperidine 
• 869937-03-1 4-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzoic acid 
• 876126-60-2 4-amino-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide 
• 3932-97-6 2,4-dichloro-5-trifluoromethylpyrimidine 

Downstream Products

• 1226992-20-6 4-{4-[2-(methanesulphonyl-methyl-amino)-4-methyl-benzylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1227830-54-7 3-methoxy-N-(1-methyl-piperidin-4-yl)-4-[4-((S)-1-methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-pyrimidin-2-ylamino]-benzamide 
• 1227830-04-7 3-methoxy-N-(1-methyl-piperidin-4-yl)-4-(4-phenoxy-5-trifluoromethyl-pyrimidin-2-ylamino)-benzamide 
• 1245830-83-4 4-[4-((1R,2R)-2-amino-cyclohexylamino)-5-trifluoro-methyl-pyrimidin-2-ylamino]-3-methoxy-N-(1-methyl-piperidin-4-yl)benzamide 
• 1245830-87-8 4-{4-[benzyl-((1R,2R)-2-benzylamino-cyclohexyl)amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-3-methoxy-N-(1-methyl-piperidin-4-yl)benzamide 
• 1245830-14-1 4-{4-[(1R,2R)-2-(methanesulphonyl-methyl-amino)cyclopentylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-3-methoxy-N-(1-methyl-piperidin-4-yl)benzamide 
• 1245829-72-4 4-{4-[(1R,2R)-2-(methanesulphonyl-methyl-amino)cyclohexylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-3-methoxy-N-(1-methyl-piperidin-4-yl)benzamide 
• 1245830-97-0 4-[4-((1R,2R)-2-amino-cyclopentylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3-methoxy-N-(1-methyl-piperidin-4-yl)benzamide 
• 1383682-14-1 C₂₈H₃₀F₃N₇O₃ 
• 1283689-51-9 4-{4-[(1R,2R)-1-(methanesulphonyl-methyl-amino)-indan-2-yloxy]-5-trifluoromethyl-pyrimidin-2-ylamino}-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1283691-19-9 4-[4-((1R,2R)-2-amino-cyclopentyloxy)-5-trifluoromethyl-pyrimidin-2-ylamino]-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1283690-30-1 4-[4-((1R,2R)-1-acetylamino-indan-2-yloxy)-5-trifluoromethyl-pyrimidin-2-ylamino]-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide 
• 1257258-47-1 4-[4-((1R,2R)-1-acetylaminoindan-2-ylamino)-5-trifluoromethylpyrimidin-2-ylamino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide 

Relevant academic research and scientific papers

Protein Kinase Conjugates and Inhibitors

The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kin

OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R5 to R10, A, L1, B, m and p are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS

The present invention encompasses compounds of general formulae (1a) and (1b), wherein the groups R1 to R5, A, Q, m, n, p and q are defined as in claim 1, which are FAK/PTK2 inhibitors and thus suitable for the treatment of diseases

NEW COMPOUNDS

The present invention encompasses compounds of general formulae (1a) and (1b) wherein the groups R1 to R5, A, Q, m, n, p and q are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or

NEW COMPOUNDS

The present invention includes compounds of general Formula (1), wherein A, X, R1 and R2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.

2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The present invention encompasses compounds of general formula (1) wherein R1-R3 and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.

SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER

The present invention encompasses compounds of general formula (1) wherein B, R1 to R5, Rx, m and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use in such treatment.

2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION

The present invention encompasses compounds of general formula (1), wherein A, B, R1 to R5, Rx m, n and p are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and the use thereof [as] medicaments.